Le Lézard
Classified in: Health, Business
Subject: PER

Nueterra Capital and its affiliates announce Scott C. Palecki as General Counsel


LEAWOOD, Kan., May 18, 2018 /PRNewswire/ -- The Chairman of Nueterra Capital would like to announce the hiring of Scott C. Palecki as General Counsel and Ms. Alex Knudson as Legal Project Manager for Nueterra Capital and its affiliates and subsidiaries which include NueHealth Holdings, NueHealth, Muve Health, ValueHealth, Healthcare RE, and Benefit Management.

Scott C. Palecki

Palecki is a veteran healthcare attorney with over 20 years of proven and steadfast private practice experience.  Scott has participated in hundreds of healthcare and corporate transactions including the development, management and syndication of over 100 hospitals and ambulatory surgical centers throughout the United States.

"We are very fortunate Mr. Palecki has joined the Nueterra team.  He brings vast experience in business and healthcare, and his knowledge and leadership will be invaluable in helping us achieve our mission of implementing value-based care to the United States healthcare delivery system," said Chairman Daniel R. Tasset.  "We admire his success in facing difficult adversaries, tackling tough issues, and achieving changes in healthcare." 

Knudson has 15 years of executive business and project management experience in the legal healthcare field, real estate, land development, and finance industries.  Alex has participated in numerous contract negotiations, managed a land portfolio of several hundred acres in excess of $165 million and delivered new projects across targeted markets.

"We are excited to add Ms. Knudson to our team. Her proven and diligent track record of analytics, project management and tenacity will help keep us on target to achieve our sizable goals to implement value-based care to the United States healthcare delivery system," said Chairman Daniel R. Tasset.  

About Nueterra Capital

Nueterra Capital is a private equity investment and advisory firm with an exclusive focus on healthcare. Leveraging a deep understanding of key industry drivers, Nueterra Capital invests in entrepreneurs with innovative minds, while providing professional expertise and back office resources to improve their bottom line performance and drive growth. Nueterra Capital has invested in hundreds of new ventures and continuously delivers the resources and strategic direction that allow our partners to advance and improve every aspect of healthcare.

 

Nueterra Capital

SOURCE Nueterra Capital


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIOŽ (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: